文章很好，可惜读不了。
EGFR抑制剂（EGFR TKIs）无论是小分子药物还是单克隆抗体，均具有良好的安全性和耐受性，常见不良反应有皮肤毒性和腹泻，罕见不良反应有间质性肺炎、肝功能异常、口腔炎、脱发、口腔干燥等，无威胁患者生命的血液学毒性。与化疗毒副反应的处理措施不同，应用此类药物出现不良反应并非停药的指征，反而是肿瘤对靶向药物敏感的临床信号。许多研究发现皮疹与EGFR TKIs治疗的疗效相关，中重度皮疹患者总体生存明显优于轻度或无皮疹的患者。
本帖最后由 老马 于 2012-1-11 13:26 编辑
EGFR基因突变和高表达与疗效的关系
本帖最后由 老马 于 2012-1-11 13:38 编辑
阿瓦斯丁联用特罗凯
http://cancergrace.org/lung/2010/06/25/update-on-atlas-overall-survival/
本帖最后由 老马 于 2012-1-15 14:52 编辑
最近老爸胃口不错，经常有练练书法，但还是懒得锻炼身体。
今天买了美国雅培安素Ensure成人复合蛋白质营养粉397g，和润肤霜。
本帖最后由 老马 于 2012-1-13 21:20 编辑
爱必妥和阿瓦斯丁的比较
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
==================================================
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
支持一下，辛苦，可惜还是看不懂。
马哥你好，看了你的贴子感觉前瞻性很好。目前老爸就用特辛联用方案？近况如何？我爸也是鳞型，不知下步怎么走呢，http://www.yuaigongwu.com/thread-5009-1-1.html，请赐教！
最近有浓痰，买了沐舒坦和复方鲜竹沥口服液。:)
下周三去检查肿瘤指标。
肺癌气管介入治疗方案